Insulin aspart Sanofi® receives EU marketing authorization, broadening options and increasing treatment choice for people with diabetes

PARIS, France I July 03, 2020 I Insulin aspart Sanofi® (insulin aspart 100 Units/mL) has received EU marketing authorization, and will provide another treatment option for adults, adolescents and children aged 1 year and above who have diabetes. The decision follows recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Insulin aspart Sanofi® rounds out Sanofi’s comprehensive insulin portfolio which already includes two rapid-acting insulin analogs approved by European regulators.

SOURCE: Sanofi

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up